Eli Lilly & Co. vs. Sarepta Therapeutics,, Inc. Common Stock
Eli Lilly & Co. (LLY) comes out ahead, leading on 6 of 8 compared factors.
Size & Scale
| LLY | SRPT | |
|---|---|---|
| Market Cap | $1.05 trillion | $1.97 billion |
| Revenue (TTM) | $79.67 billion | $1.97 billion |
| Net Income (TTM) | $26.71 billion | $-136,725,000 |
LLY leads on 3 of 3 size & scale factors.
Valuation
| LLY | SRPT | |
|---|---|---|
| P/E Ratio | 39.77 | — |
| Price / Book | 31.14 | 1.29 |
| Price / Sales | 13.24 | 1.00 |
SRPT leads on 2 of 2 valuation factors.
Profitability
| LLY | SRPT | |
|---|---|---|
| Net Margin | 33.53% | -6.93% |
| Return on Equity | 78.84% | -8.95% |
LLY leads on 2 of 2 profitability factors.
Dividend
| LLY | SRPT | |
|---|---|---|
| Dividend Yield | 0.58% | — |
| Payout Ratio | 23.23 | — |
LLY and SRPT split the dividend factors evenly.
Risk & Sentiment
| LLY | SRPT | |
|---|---|---|
| Short Interest | 1.29% | 9.38% |
LLY leads on 1 of 1 risk & sentiment factors.
Dig deeper: LLY overview, LLY financials, SRPT overview, SRPT financials.
Comparisons use delayed, cached fundamental data and cover only the factors shown. For informational purposes only — not investment advice.